

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

IN RE: GLUCAGON-LIKE	:	CIVIL ACTION
PEPTIDE-1 RECEPTOR AGONISTS	:	
(GLP-1 RAS) PRODUCTS	:	
LIABILITY LITIGATION	:	
<hr/>	:	
	:	
THIS DOCUMENT RELATES TO:	:	MDL No. 3094
	:	24-md-3094
<i>Middleton v. Novo Nordisk A/S</i>	:	
Case No. 2:24-cv-3166	:	HON. KAREN SPENCER MARSTON
	:	
<i>Rogers v. Novo Nordisk A/S</i>	:	
Case No. 2:24-cv-3177	:	
<hr/>		

ORDER

AND NOW, this 15th day of January, 2025, upon consideration of the JPML’s December 12, 2024 Transfer Order, which expands the scope of this MDL “to include the additional Novo Nordisk GLP-1 RA drug Saxenda” (*see* Doc. No. 314), it is **ORDERED** that the **STAY IS LIFTED** in *Middletown v. Novo Nordisk A/S* (Case No. 2:24-cv-3166) and *Rogers v. Novo Nordisk A/S* (Case No. 2:24-cv-3177). Both cases shall proceed as part of the MDL.

BY THE COURT:

/s/ Karen Spencer Marston
KAREN SPENCER MARSTON, J.